Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1315-1319

  Autio, Anu ^a   Vainio, Petri J ^a,b   Suilamo, Sami ^a   Mali, Antti ^c   Vainio, Jani ^b   Saanijoki, Tiina ^a   Noponen, Tommi ^a   Ahtinen, Helena ^a   Luoto, Pauliina ^a   Teräs, Mika ^a   Jalkanen, Sirpa ^d   Roivainen, Anne ^a,e  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b Biotie Therapies Corp   (Finland)

^c MAP Medical Technologies Oy   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Antibody; Nuclear imaging; Rabbit; Radioiodination; Vascular adhesion protein 1

Indexed keywords

BTT-1023; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1;

ANIMAL EXPERIMENT; ARTICLE; CIRCULATION; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RABBIT; RADIATION DOSE; RADIOACTIVITY; RADIOIODINATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNOVITIS;

ANTIBODY; NUCLEAR IMAGING; RABBIT; RADIOIODINATION; VASCULAR ADHESION PROTEIN-1;

AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; ANTIBODIES, MONOCLONAL; CELL ADHESION MOLECULES; HUMANS; INFLAMMATION; IODINE RADIOISOTOPES; MOLECULAR IMAGING; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RABBITS; RADIATION DOSAGE;

EID: 84881445821     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.120295     Document Type: Article

References (18)

1. Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science. 1992;257:1407-1409.
2. Salmi M, Tohka S, Berg EL, Butcher EC, Jalkanen S. Vascular adhesion protein 1 (VAP-1) mediates lymphocyte subtype-specific, selectin-independent recognition of vascular endothelium in human lymph nodes. J Exp Med. 1997;186:589-600.
3. Merinen M, Irjala H, Salmi M, Jaakkola I, Hänninen A, Jalkanen S. Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am J Pathol. 2005;166:793-800.
4. Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med. 1993;178:2255-2260.
5. Marttila-Ichihara F, Smith DJ, Stolen C, et al. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum. 2006;54:2852-2862.
6. Salmi M, Yegutkin GG, Lehvonen R, Koskinen K, Salminen T, Jalkanen S. A cell surface amine oxidase directly controls lymphocyte migration. Immunity. 2001;14:265-276.
7. Madej A, Reich A, Orda A, Szepietowski JC. Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. J Eur Acad Dermatol Venereol. 2007;21:72-78.
8. Kirton CM, Laukkanen ML, Nieminen A, et al. Function-blocking antibodies to human vascular adhesion protein-1: a potential anti-inflammatory therapy. Eur J Immunol. 2005;35:3119-3130.
9. Boerman OC, Oyen WJ. Immuno-PET of cancer: a revival of antibody imaging. J Nucl Med. 2011;52:1171-1172.
10. Mikkola J, Smith D, Vainio J, Vainio P, Vuorio P, inventors. Biotie Therapies Corporation, assignee. Novel fully human anti-vap-1 monoclonal antibodies. Patent WO2008129124 A1. October 30, 2008.
11. Jaakkola K, Nikula T, Holopainen R, et al. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am J Pathol. 2000;157:463-471.
12. Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams D. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol. 2002;169:983-992.
13. Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, et al. Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis. Basic Clin Pharmacol Toxicol. 2005;96:429-435.
14. 124I-rituximab in patients with rheumatoid arthritis. Hum Antibodies. 2011;20:7-14.
15. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002;94:1484-1493.
16. Farmakis G, Brandau W, Hellwig D, et al. PET imaging with p-[I-124]iodo-lphenylalanine as a new tool for diagnosis and postoperative control in patients with glioma. Clin Nucl Med. 2008;33:441-442.
17. 124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304-310.
18. 124I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011;52:1173-1180.